Wall Street Zen Downgrades Sagimet Biosciences (NASDAQ:SGMT) to Sell

Sagimet Biosciences (NASDAQ:SGMT) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other research analysts also recently weighed in on SGMT. Citizens Jmp increased their price objective on shares of Sagimet Biosciences from $12.00 to $29.00 and gave the company a “market outperform” rating in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Friday, July 17th. Canaccord Genuity Group boosted their target price on shares of Sagimet Biosciences from $49.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Oppenheimer restated an “outperform” rating on shares of Sagimet Biosciences in a research note on Friday, May 1st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Sagimet Biosciences in a report on Friday. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Sagimet Biosciences currently has an average rating of “Moderate Buy” and an average target price of $29.17.

Sagimet Biosciences Stock Performance

Shares of NASDAQ:SGMT opened at $10.55 on Friday. The firm has a market cap of $343.72 million, a price-to-earnings ratio of -8.24 and a beta of 3.37. The business has a 50-day simple moving average of $7.51 and a two-hundred day simple moving average of $6.57. Sagimet Biosciences has a fifty-two week low of $4.50 and a fifty-two week high of $10.60.

Sagimet Biosciences (NASDAQ:SGMT) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). As a group, research analysts predict that Sagimet Biosciences will post -1.2 earnings per share for the current year.

Insider Buying and Selling at Sagimet Biosciences

In other news, insider Elizabeth Rozek sold 10,545 shares of Sagimet Biosciences stock in a transaction on Monday, July 20th. The shares were sold at an average price of $7.76, for a total transaction of $81,829.20. Following the transaction, the insider owned 224,414 shares in the company, valued at $1,741,452.64. This trade represents a 4.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Kemble sold 20,206 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $9.95, for a total transaction of $201,049.70. Following the sale, the director directly owned 62,161 shares of the company’s stock, valued at approximately $618,501.95. The trade was a 24.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 113,646 shares of company stock valued at $920,491. Insiders own 11.50% of the company’s stock.

Hedge Funds Weigh In On Sagimet Biosciences

A number of institutional investors have recently bought and sold shares of SGMT. Dimensional Fund Advisors LP lifted its position in Sagimet Biosciences by 99.4% during the first quarter. Dimensional Fund Advisors LP now owns 271,217 shares of the company’s stock valued at $1,415,000 after purchasing an additional 135,178 shares in the last quarter. Renaissance Technologies LLC increased its position in Sagimet Biosciences by 82.6% in the first quarter. Renaissance Technologies LLC now owns 625,469 shares of the company’s stock worth $3,268,000 after buying an additional 282,969 shares in the last quarter. Dumac Inc. bought a new position in shares of Sagimet Biosciences in the fourth quarter worth about $421,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Sagimet Biosciences in the fourth quarter worth about $30,000. Finally, Virtu Financial LLC purchased a new position in shares of Sagimet Biosciences during the 4th quarter valued at about $62,000. 87.86% of the stock is owned by institutional investors.

Key Stories Impacting Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: FDA clears Phase 3 acne study: The FDA accepted Sagimet’s Investigational New Drug application and issued a “Study May Proceed” letter for a U.S. Phase 3 trial of oral, once-daily denifanstat in moderate to severe acne. The trial is expected to begin in the second half of 2026 and enroll approximately 800 patients, including about 450 adolescents. This advances the company’s lead program into a late-stage study and could materially improve its commercial prospects if efficacy and safety are confirmed. FDA Study May Proceed letter and IND clearance
• Positive Sentiment: Citizens JMP raises price target: Citizens JMP increased its target for Sagimet from $12 to $29 and maintained a “Market Outperform” rating. The higher target reflects stronger expectations for denifanstat’s development following the FDA clearance. Citizens JMP price target update
• Positive Sentiment: Additional analyst support: Canaccord Genuity also issued a bullish outlook for SGMT, adding to generally positive Wall Street sentiment around the company’s pipeline and potential future appreciation. Canaccord Genuity Sagimet forecast
• Negative Sentiment: Continued operating losses: Sagimet reported a quarterly loss of $0.26 per share, slightly worse than the $0.25 analyst consensus, while HC Wainwright lowered its fourth-quarter loss estimate to $0.32 per share. The company remains dependent on clinical progress and likely future financing.
• Negative Sentiment: Insider selling: Director George Kemble sold 20,206 shares for approximately $201,050, reducing his direct ownership by 24.5%. Although the sale may be routine, it could temper investor sentiment following the recent rally. George Kemble insider sale

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.